← All organizations
Highest phase reached
Phase 4
First clinical trial
Mar 1, 2002First marketed drug
Nov 21, 2019First NDA
Nov 21, 2019Last known activity
Oct 14, 2024
Acquired by Angelini on Jan 3, 2021
Timeline
1990s
- Jan 1, 1993
Arvelle— Founded
2010s
- Nov 21, 2019
cenobamate— Marketing Organization
- Nov 21, 2019
cenobamate— NDA Organization
2020s
- Jan 3, 2021
Angelini— Acquired By
Drugs by trial phase (15 distinct, 42 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (3 own, 0 via acquisition)
Phase 2 (5 own, 0 via acquisition)
Phase 1 (6 own, 0 via acquisition)
Indications
Studied for
- Constipation
- Diabetic Neuropathies
- Drug Resistant Epilepsy
- Epilepsies, Partial
- Epilepsy
- Epilepsy, Complex Partial
- Epilepsy, Generalized
- Epilepsy, Partial, Motor
- Essential Tremor
- Headache
- Herpes Zoster
- Lennox Gastaut Syndrome
- Migraine Disorders
- Mononeuropathies
- Movement Disorders
- Neuralgia
- Neuralgia, Postherpetic
- Peripheral Nervous System Diseases
- Polyneuropathies
- Schizophrenia
- Seizures
- Syndrome
- Tremor
Marketed drugs (1)
Recent trials (50)
- NCT04513860Lead sponsorN/A—
- NCT04513860Study directorN/A—
- NCT06453213Lead sponsorPhase 4Oct 14, 2024
- NCT05572255Lead sponsorPhase 1Sep 27, 2022
- NCT05388435Study directorPhase 1/Phase 2Sep 12, 2022
- NCT05388435Lead sponsorPhase 1/Phase 2Sep 12, 2022
- NCT05219617Lead sponsorPhase 3Apr 28, 2022
- NCT05219617Study directorPhase 3Apr 28, 2022
- NCT05067634Lead sponsorPhase 3Jan 31, 2022
- NCT05067634Study directorPhase 3Jan 31, 2022
- NCT04791553Lead sponsorPhase 1Jun 17, 2021
- NCT04791553Study chairPhase 1Jun 17, 2021
- NCT04903314Lead sponsorPhase 1May 27, 2021
- NCT04903314Study directorPhase 1May 27, 2021
- NCT04557085Lead sponsorPhase 3Feb 28, 2021
Details
- Founded
- Fair Lawn, NJ, US Jan 1, 1993
- First NDA
- Nov 21, 2019
- Last known activity
- Oct 14, 2024